← All trials
NCT04067115
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2019
- Primary completion
- Jul 31, 2023
- Completion date
- Dec 31, 2025
- First posted
- —
- Last posted
- —
- Enrollment
- 45
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sarcoma Alliance for Research through CollaborationLead sponsor
- National Institutes of Health (NIH)Collaborator
- National Cancer Institute (NCI)Collaborator
- National Cancer Institute (NCI)Study director
- University of PennsylvaniaOverall official - principal investigator
- Janssen Pharmaceutica NVCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.